1-3 of 3
Mary Crann
Close
Sort by
Journal Articles

Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) Breaks Plateau Responses Following Initial Induction Therapy in Multiple Myeloma: Results of a Phase II Pilot Study.

Megan C. Manco, Tomer Mark, David S Jayabalan, Faiza Zafar, Roger Pearse, Mary Crann, John P. Leonard, Selina Chen-Kiang, Morton Coleman, Ruben Niesvizky
Journal: Blood
Blood (2009) 114 (22): 2311.
https://doi.org/10.1182/blood.V114.22.2311.2311
Published: 2009
Journal Articles

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma.

Tomer Mark, MD, Morton Coleman, MD, David S Jayabalan, BSMS, Roger Pearse, MD/PhD, Faiza Zafar, PA, Scott Ely, MD, MPH, Megan C. Manco, Mary Crann, RN, John P. Leonard, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD
Journal: Blood
Blood (2009) 114 (22): 1861.
https://doi.org/10.1182/blood.V114.22.1861.1861
Published: 2009
Journal Articles

A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.

Ruben Niesvizky, MD, Scott Ely, MD, MPH, David S Jayabalan, Megan C. Manco, Seema Singhal, MD, Mary Crann, Rachel Courtney, Cynthia DuFresne, Keith D. Wilner, PhD, Isan Chen, MD, Tomer Mark, MD, John P. Leonard, MD, Morton Coleman, MD, Maurizio DiLiberto, PhD, Xiangao Huang, PhD, Selina Chen-Kiang, PhD
Journal: Blood
Blood (2009) 114 (22): 1877.
https://doi.org/10.1182/blood.V114.22.1877.1877
Published: 2009